# Biotech Daily Digest ‚Äî 2026-01-27

**41 items from 3 sources**

## Summary by Source

- Endpoints News: 8 items
- Fierce Biotech: 6 items
- arXiv q-bio: 27 items


## Endpoints News

- **[AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal](https://endpoints.news/astrazeneca-ends-work-on-cardio-drug-lisata-and-qilu-terminate-deal/)**  
  _Tue, 27 Jan 2026 14:31:24 +0000_  
  Plus, news about Vial, Skyhawk and Gimv:

 AstraZeneca stops cardio drug: The UK pharma giant has terminated a Phase 1 of an oral cardio drug candidate called AZD0233, according ...

- **[FDA greenlights Life Biosciences' gene therapy study to rewind the age of cells](https://endpoints.news/exclusive-fda-greenlights-gene-therapy-study-to-rewind-the-age-of-cells/)**  
  _Tue, 27 Jan 2026 13:00:47 +0000_  
  One of the biggest theories about the cause of aging, and how to slow and potentially even reverse it, is about to be put to the test.
 Life Biosciences, a biotech startup co-founded by Harvard ...

- **[Roche‚Äôs obesity shot posts decent weight loss in mid-stage test, heads to Phase 3](https://endpoints.news/roches-obesity-shot-posts-decent-weight-loss-in-mid-stage-test-heads-to-phase-3/)**  
  _Tue, 27 Jan 2026 12:09:37 +0000_  
  Roche‚Äôs most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma

- **[TRexBio gets another $50M to bring more Treg candidates into the clinic](https://endpoints.news/trexbio-gets-another-50m-to-bring-more-treg-candidates-into-the-clinic/)**  
  _Tue, 27 Jan 2026 12:00:48 +0000_  
  Bay Area startup TRexBio has bolstered its 2024 Series B with an additional $50 million to fund the biotech's clinical development in the burgeoning Treg space.

 The biotech, founded in 2018 by SV Health Investors ...

- **[IRA drug pricing petitions pile up at the Supreme Court](https://endpoints.news/ira-drug-pricing-petitions-pile-up-at-the-supreme-court/)**  
  _Mon, 26 Jan 2026 20:21:13 +0000_  
  Novartis is now the sixth drugmaker to bring its Inflation Reduction Act challenge to the Supreme Court as the pharma industry‚Äôs yearslong court battle comes to a head.

 Novartis was the last drugmaker expected to ...

- **[Catalent plans to close Belgium cell therapy site](https://endpoints.news/catalent-plans-to-close-belgium-cell-therapy-site/)**  
  _Mon, 26 Jan 2026 17:45:49 +0000_  
  Catalent plans to close a cell therapy site in Gosselies, Belgium, due to ‚Äúchanging market dynamics and customer needs,‚Äù a company spokesperson confirmed to Endpoints News. 

 The contract developer and manufacturer is considering transitioning ...

- **[Sarepta touts three-year Duchenne gene therapy data after patient deaths](https://endpoints.news/sarepta-touts-three-year-duchenne-gene-therapy-data-after-patient-deaths/)**  
  _Mon, 26 Jan 2026 16:17:47 +0000_  
  Sarepta said the effects of its Duchenne muscular dystrophy gene therapy were durable three years after treatment, based on longer-term findings from patients in its key clinical trial.

 The data come after a tumultuous year ...

- **[Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing](https://endpoints.news/genyro-licences-dna-builder-from-caltech-dizal-targets-hong-kong-listing/)**  
  _Mon, 26 Jan 2026 15:07:04 +0000_  
  Plus, news about United Therapeutics and Fortitude Biomedicines:

 üèóÔ∏è San Diego startup licenses 'DNA construction' tech: Genyro gets exclusive rights to the technology, dubbed ‚ÄúSidewinder,‚Äù which was developed by researchers at ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/united-therapeutics-bioengineered-temporary-liver-shows-promise-phase-1-trial" hreflang="en">United Therapeutics' bioengineered temporary liver shows promise in phase 1 trial</a>](https://www.fiercebiotech.com/medtech/united-therapeutics-bioengineered-temporary-liver-shows-promise-phase-1-trial)**  
  _Jan 27, 2026 8:31am_  
  United Therapeutics‚Äô bioengineered external liver assist system developed to treat patients with acute forms of chronic liver failure proved promising based on early phase 1 trial results.

- **[<a href="https://www.fiercebiotech.com/medtech/ai-native-outpatient-surgery-startup-oath-surgical-inks-nvidia-partnership" hreflang="en">'AI-native' outpatient surgery startup Oath Surgical inks Nvidia partnership</a>](https://www.fiercebiotech.com/medtech/ai-native-outpatient-surgery-startup-oath-surgical-inks-nvidia-partnership)**  
  _Jan 27, 2026 5:16am_  
  Portland, Oregon-based startup Oath Surgical is partnering with tech giant Nvidia to enhance Oath‚Äôs AI-powered outpatient surgery center operating system.

- **[<a href="https://www.fiercebiotech.com/medtech/reveal-genomics-unveils-triumvirate-new-roles-its-co-founders" hreflang="en">Reveal Genomics unveils triumvirate of new roles for its co-founders </a>](https://www.fiercebiotech.com/medtech/reveal-genomics-unveils-triumvirate-new-roles-its-co-founders)**  
  _Jan 27, 2026 8:10am_  
  Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its founding members.

- **[<a href="https://www.fiercebiotech.com/biotech/roches-glp1gip-drug-carmot-sees-225-weight-loss-readies-phase-3-trial" hreflang="en">Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial</a>](https://www.fiercebiotech.com/biotech/roches-glp1gip-drug-carmot-sees-225-weight-loss-readies-phase-3-trial)**  
  _Jan 27, 2026 4:53am_  
  Roche‚Äôs dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company‚Äôs decision to move the asset into phase 3 studies in the coming weeks.

- **[<a href="https://www.fiercebiotech.com/biotech/european-investment-firm-gimv-gives-new-activity-life-science-sector" hreflang="en">European investment firm Gimv calls it quits on new life science financing</a>](https://www.fiercebiotech.com/biotech/european-investment-firm-gimv-gives-new-activity-life-science-sector)**  
  _Jan 26, 2026 1:38pm_  
  European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its long-term investments and finding new value in four other key areas.

- **[<a href="https://www.fiercebiotech.com/biotech/fortitude-has-faith-molecular-glue-degraders-can-overcome-adc-resistance" hreflang="en">Fortitude has faith molecular glue degraders can overcome ADC resistance</a>](https://www.fiercebiotech.com/biotech/fortitude-has-faith-molecular-glue-degraders-can-overcome-adc-resistance)**  
  _Jan 26, 2026 10:26am_  
  What do you get when you insert a molecular glue degrader into an antibody-drug conjugate? Fortitude Biomedicines is in the process of finding out.


## arXiv q-bio

- **[How Information Evolves: Stability-Driven Assembly and the Emergence of a Natural Genetic Algorithm](https://arxiv.org/abs/2601.17061)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17061v1 Announce Type: new 
Abstract: Information can evolve as a physical consequence of non-equilibrium dynamics, even in the absence of genes, replication, or predefined fitness functions. We present Stability-Driven Assembly (SDA), a framework in which stochastic assembly combined with differential pers‚Ä¶

- **[Domain-Aware Geometric Multimodal Learning for Multi-Domain Protein-Ligand Affinity Prediction](https://arxiv.org/abs/2601.17102)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17102v1 Announce Type: new 
Abstract: The accurate prediction of protein-ligand binding affinity is important for drug discovery yet remains challenging for multi-domain proteins, where inter-domain dynamics and flexible linkers govern molecular recognition. Current geometric deep learning methods typically‚Ä¶

- **[FASTR: Reimagining FASTQ via Compact Image-inspired Representation](https://arxiv.org/abs/2601.17184)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17184v1 Announce Type: new 
Abstract: Motivation: High-throughput sequencing (HTS) enables population-scale genomics but generates massive datasets, creating bottlenecks in storage, transfer, and analysis. FASTQ, the standard format for over two decades, stores one byte per base and one byte per quality sco‚Ä¶

- **[Unsupervised sleep-like intra- and inter-layer plasticity categorizes and improves energy efficiency in a multilayer spiking network](https://arxiv.org/abs/2601.17523)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17523v1 Announce Type: new 
Abstract: Sleep is thought to support memory consolidation and the recovery of optimal energetic regime by reorganizing synaptic connectivity, yet how plasticity across hierarchical brain circuits contributes to abstraction and energy efficiency remains unclear. Here we study a s‚Ä¶

- **[GenAI-Net: A Generative AI Framework for Automated Biomolecular Network Design](https://arxiv.org/abs/2601.17582)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17582v1 Announce Type: new 
Abstract: Biomolecular networks underpin emerging technologies in synthetic biology-from robust biomanufacturing and metabolic engineering to smart therapeutics and cell-based diagnostics-and also provide a mechanistic language for understanding complex dynamics in natural and ec‚Ä¶

- **[Travelling Waves in Wolbachia Spread Dynamics](https://arxiv.org/abs/2601.17590)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17590v1 Announce Type: new 
Abstract: Wolbachia, a maternally transmitted endosymbiont, offers a powerful biological control strategy for mosquito-borne diseases such as dengue, Zika, and malaria. We develop an integro-difference equation (IDE) model that integrates Wolbachia's nonlinear growth with spatial‚Ä¶

- **[Quantitative cancer-immunity cycle modeling to optimize bevacizumab and atezolizumab combination therapy for advanced renal cell carcinoma](https://arxiv.org/abs/2601.17669)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17669v1 Announce Type: new 
Abstract: The incidence of advanced renal cell carcinoma(RCC) has been rising, presenting significant challenges due to the limited efficacy and severe side effects of traditional radiotherapy and chemotherapy. While combination immunotherapies show promise, optimizing treatment‚Ä¶

- **[Tracking dynamics of superspreading through contacts, exposures, and transmissions in edge-based network epidemics](https://arxiv.org/abs/2601.17763)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17763v1 Announce Type: new 
Abstract: Infectious disease superspreading caused by heterogeneity in contact behavior has been observed to be an important determinant of epidemic dynamics and size in both empirical and theoretical settings. However, it has also been observed that the importance of this type o‚Ä¶

- **[A model for a population of trees structured by phenological traits](https://arxiv.org/abs/2601.18214)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18214v1 Announce Type: new 
Abstract: In the context of global warming, tree populations rely on two primary mechanisms of adaptation: phenotypic plasticity, which enables individuals to adjust their behavior in response to environmental stress, and genetic evolution, driven by natural selection and genetic‚Ä¶

- **[Closed Eyes and Coil Size -- Effects on Motor Threshold and Intracortical Inhibition, measured with TMS](https://arxiv.org/abs/2601.18286)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18286v1 Announce Type: new 
Abstract: Rationale: Transcranial magnetic stimulation (TMS)-based measures such as resting motor threshold (RMT) and short interval intracortical inhibition (SICI) are widely employed to study motor cortical and corticospinal tract function, and effects of diseases and drug ther‚Ä¶

- **[Chemotaxis-inspired PDE models of airborne infectious disease transmission: epidemiologically-motivated mathematical and numerical analyses](https://arxiv.org/abs/2601.18703)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18703v1 Announce Type: new 
Abstract: Partial differential equation (PDE) models for infectious diseases, while less common than their ordinary differential equation (ODE) counterparts, have found successful applications for many years. Such models are typically of reaction-diffusion type, and model spatial‚Ä¶

- **[Semi-Supervised Domain Adaptation with Latent Diffusion for Pathology Image Classification](https://arxiv.org/abs/2601.17228)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17228v1 Announce Type: cross 
Abstract: Deep learning models in computational pathology often fail to generalize across cohorts and institutions due to domain shift. Existing approaches either fail to leverage unlabeled data from the target domain or rely on image-to-image translation, which can distort tis‚Ä¶

- **[BMDS-Net: A Bayesian Multi-Modal Deep Supervision Network for Robust Brain Tumor Segmentation](https://arxiv.org/abs/2601.17504)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17504v1 Announce Type: cross 
Abstract: Accurate brain tumor segmentation from multi-modal magnetic resonance imaging (MRI) is a prerequisite for precise radiotherapy planning and surgical navigation. While recent Transformer-based models such as Swin UNETR have achieved impressive benchmark performance, th‚Ä¶

- **[Motif Diversity in Human Liver ChIP-seq Data Using MAP-Elites](https://arxiv.org/abs/2601.17808)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.17808v1 Announce Type: cross 
Abstract: Motif discovery is a core problem in computational biology, traditionally formulated as a likelihood optimization task that returns a single dominant motif from a DNA sequence dataset. However, regulatory sequence data admit multiple plausible motif explanations, refl‚Ä¶

- **[The Quantum Cliff: A Critical Proton Tunneling Threshold Determines Clinical Severity in RPE65-Mediated Retinal Disease](https://arxiv.org/abs/2601.18435)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18435v1 Announce Type: cross 
Abstract: Predicting clinical severity from genotype remains a fundamental challenge in molecular medicine, particularly for enzymes whose function depends on sub-atomic-scale geometry. Mutations in the \textit{RPE65} isomerohydrolase cause Leber Congenital Amaurosis (LCA) and‚Ä¶

- **[LaCoGSEA: Unsupervised deep learning for pathway analysis via latent correlation](https://arxiv.org/abs/2601.18604)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18604v1 Announce Type: cross 
Abstract: Motivation: Pathway enrichment analysis is widely used to interpret gene expression data. Standard approaches, such as GSEA, rely on predefined phenotypic labels and pairwise comparisons, which limits their applicability in unsupervised settings. Existing unsupervised‚Ä¶

- **[TwinPurify: Purifying gene expression data to reveal tumor-intrinsic transcriptional programs via self-supervised learning](https://arxiv.org/abs/2601.18640)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18640v1 Announce Type: cross 
Abstract: Advances in single-cell and spatial transcriptomic technologies have transformed tumor ecosystem profiling at cellular resolution. However, large scale studies on patient cohorts continue to rely on bulk transcriptomic data, where variation in tumor purity obscures tu‚Ä¶

- **[Conditioned Generative Modeling of Molecular Glues: A Realistic AI Approach for Synthesizable Drug-like Molecules](https://arxiv.org/abs/2601.18716)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.18716v1 Announce Type: cross 
Abstract: Alzheimer's disease (AD) is marked by the pathological accumulation of amyloid beta-42 (Abeta-42), contributing to synaptic dysfunction and neurodegeneration. While extracellular amyloid plaques are well-studied, increasing evidence highlights intracellular Abeta-42 a‚Ä¶

- **[Physiology-Informed Generative Multi-Task Network for Contrast-Free CT Perfusion](https://arxiv.org/abs/2505.22673)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2505.22673v2 Announce Type: replace 
Abstract: Perfusion imaging is extensively utilized to assess hemodynamic status and tissue perfusion in various organs. Computed tomography perfusion (CTP) imaging plays a key role in the early assessment and planning of stroke treatment. While CTP provides essential perfusi‚Ä¶

- **[NeuroKoop: Neural Koopman Fusion of Structural-Functional Connectomes for Identifying Prenatal Drug Exposure in Adolescents](https://arxiv.org/abs/2508.16414)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2508.16414v2 Announce Type: replace 
Abstract: Understanding how prenatal exposure to psychoactive substances such as cannabis shapes adolescent brain organization remains a critical challenge, complicated by the complexity of multimodal neuroimaging data and the limitations of conventional analytic methods. Exi‚Ä¶

- **[Complex-valued Phase Synchrony Reveals Directional Coupling in FMRI and Tracks Medication Effects](https://arxiv.org/abs/2509.13481)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2509.13481v2 Announce Type: replace 
Abstract: Understanding interactions in complex systems requires capturing the relative timing of coupling, not only its strength. Phase synchronization captures this timing, yet most methods either reduce the phase to its cosine or collapse it into scalar indices such as the‚Ä¶

- **[Multiview Random Vector Functional Link Network for Predicting DNA-Binding Proteins](https://arxiv.org/abs/2409.02588)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2409.02588v2 Announce Type: replace-cross 
Abstract: The identification of DNA-binding proteins (DBPs) is essential due to their significant impact on various biological activities. Understanding the mechanisms underlying protein-DNA interactions is essential for elucidating various life activities. In recent ye‚Ä¶

- **[Contrastive Consolidation of Top-Down Modulations Achieves Sparsely Supervised Continual Learning](https://arxiv.org/abs/2505.14125)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2505.14125v3 Announce Type: replace-cross 
Abstract: Biological brains learn continually from a stream of unlabeled data, while integrating specialized information from sparsely labeled examples without compromising their ability to generalize. Meanwhile, machine learning methods are susceptible to catastrophic‚Ä¶

- **[Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery](https://arxiv.org/abs/2509.14788)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2509.14788v2 Announce Type: replace-cross 
Abstract: Accurate identification of drug-target interactions (DTI) remains a central challenge in computational pharmacology, where sequence-based methods offer scalability. This work introduces a sequence-based drug-target interaction framework that integrates structu‚Ä¶

- **[A flexible framework for structural plasticity in GPU-accelerated sparse spiking neural networks](https://arxiv.org/abs/2510.19764)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2510.19764v2 Announce Type: replace-cross 
Abstract: The majority of research in both training Artificial Neural Networks (ANNs) and modeling learning in biological brains focuses on synaptic plasticity, where learning equates to changing the strength of existing connections. However, in biological brains, struc‚Ä¶

- **[Far from the Shallow: Brain-Predictive Reasoning Embedding through Residual Disentanglement](https://arxiv.org/abs/2510.22860)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2510.22860v3 Announce Type: replace-cross 
Abstract: Understanding how the human brain progresses from processing simple linguistic inputs to performing high-level reasoning is a fundamental challenge in neuroscience. While modern large language models (LLMs) are increasingly used to model neural responses to la‚Ä¶

- **[Crossing the Functional Desert: Cascade-Driven Assembly and Feasibility Transitions in Early Life](https://arxiv.org/abs/2601.06272)**  
  _Tue, 27 Jan 2026 00:00:00 -0500_  
  arXiv:2601.06272v3 Announce Type: replace-cross 
Abstract: The origin of life poses a problem of combinatorial feasibility: How can temporally supported functional organization arise in exponentially branching assembly spaces when unguided exploration behaves as a memoryless random walk? We show that nonlinear thresho‚Ä¶
